Eversept Partners LP Has $9.15 Million Stock Position in NewAmsterdam Pharma Company N.V. $NAMS

Eversept Partners LP reduced its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 32.1% in the 1st quarter, Holdings Channel.com reports. The fund owned 285,764 shares of the company’s stock after selling 135,063 shares during the period. Eversept Partners LP’s holdings in NewAmsterdam Pharma were worth $9,147,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Duquesne Family Office LLC lifted its position in shares of NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after purchasing an additional 1,091,525 shares in the last quarter. Castle Hook Partners LP bought a new position in NewAmsterdam Pharma in the fourth quarter valued at $38,062,000. Adage Capital Partners GP L.L.C. grew its position in NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after purchasing an additional 1,062,359 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in NewAmsterdam Pharma by 96.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock valued at $60,536,000 after buying an additional 845,110 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after buying an additional 697,129 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Trading Up 2.0%

NASDAQ NAMS opened at $30.22 on Tuesday. The firm has a market capitalization of $3.53 billion, a P/E ratio of -16.88 and a beta of 0.08. The firm’s fifty day moving average price is $32.73 and its two-hundred day moving average price is $32.84. NewAmsterdam Pharma Company N.V. has a 1 year low of $21.14 and a 1 year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The firm had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. On average, research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NAMS. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Royal Bank Of Canada upped their target price on NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a report on Tuesday, June 30th. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, BMO Capital Markets began coverage on NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an “outperform” rating and a $58.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.42.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 40,000 shares of NewAmsterdam Pharma stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $30.20, for a total transaction of $1,208,000.00. Following the completion of the transaction, the chief accounting officer owned 24,353 shares in the company, valued at approximately $735,460.60. This trade represents a 62.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 12.74% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.